Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

By G. Hortobagyi, S. Stemmer, H. Burris, Y. Yap, G. Sonke, S. Paluch-Shimon, Mario Campone, K. Blackwell, F. André, E. Winer and 27 more. New England Journal of Medicine, 2016

1,638 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/6bffab4c946ffd7ff7ba4402570706a21fcbd182

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Carlos L. Arteaga
2. A. Hanker
3. D. Sudhan

In Oncology

1. N. Keen
2. M. Jorge Cardoso
3. Larry Norton
4. J. Herrmann
5. Carlos L. Arteaga
6. G. Hortobagyi
7. A. Hanker
8. D. Sudhan

In Pulmonary and Respiratory Medicine

1. Carlos L. Arteaga
2. A. Hanker
3. D. Sudhan

Citations in the corpus

• Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. (2018, methodology): “Similar to results from other ribociclib studies, ribociclib treatment effect was consistent across most prespecified subgroups, further supporting use of ribociclib-based therapy for a broad range of patients with HR-positive/HER2-negative advanced breast cancer.(6,7) Although menwere eligible for ”
• Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (2018, background): “A total of 668 patients were randomized to ribociclib plus letrozole (n1⁄4 334) and placebo plus letrozole (n1⁄4 334) between 24 January 2014 and 24 March 2015 [1].”
• Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. (2017, positive): “Consistent with emerging clinical data, the luminal subtype also showed dependence on components of the PIK3CA/mTOR andCDK4 pathways (Baselga et al., 2012; Hortobagyi et al., 2016).”
• Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations (2020, background): “ribociclib).(57) Among the TKIs, for example, sunitinib, sorafenib, vandetanib, crizotinib, vemurafenib, dasatinib, lapatinib and nilotinib have product labellingwith standard or specific warnings to serious or life-threatening risks for QT interval prolongation.”
• Overcoming Endocrine Resistance in Breast Cancer (2020, positive): “The mTORC1 inhibitor everolimus, which blocks a critical signaling node downstream PI3K, is approved in combination with aromatase inhibitors for MBCs that have progressed on endocrine therapy, regardless of PIK3CA mutational status (Baselga et al., 2012; Hortobagyi et al., 2016a).”
• 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020, positive): “The last 2 years have seen the establishment of cyclindependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC in view of the OS benefit seen in several trials,(36-42) both in the first- and second-line settings, substantial ”
• Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer (2018, neutral): “Any 40 (16) 17 (9) 20 (15) 21 (15) 12 (11) 13 (15)”